Altay Therapeutics YC 申请

Winter 2020Active

Altay Therapeutics 在 Winter 2020 批次的 Y Combinator 中作为一家 Healthcare 公司进行过。以下是：公司做什么、谁创立了它，以及其 YC 申请，按照真实 YC 表格逐题重建。

YC 批次: Winter 2020
行业: HealthcareTherapeutics
团队规模: 6
状态: Active
已发布: 2020

创始人

Ali OzesFounder
Osman OzesFounder

Altay Therapeutics 做什么

Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.

Altay Therapeutics 的 YC 申请，重建版

Y Combinator 申请

Altay Therapeutics，Winter 2020 期。来自公开数据的真实申请问题解答。

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Altay Therapeutics

Describe what your company does in 50 characters or less.

Small molecule therapies for liver disease

What is your company going to make? Please describe your product and what it does or will do.

We develop small molecule drugs that target transcription pathways to treat chronic liver diseases like fibrosis and cancer. Our lead compound has shown in mouse models not just reduction but reversal of liver fibrosis, aiming for a clinic-ready drug by end of 2021 and phase I trials mid-2022.

Where do you live now, and where would the company be based after YC?

We live and work in San Francisco and South San Francisco, CA, which will remain our base after YC.

Explain your decision regarding location.

We chose to base the company in San Francisco because that's where the biotech innovation ecosystem and our team are. It keeps us close to partners, investors, and talent relevant to small molecule therapeutic development.

21 更多回答在完整申请中

Founders, Progress, Idea, Equity, Curious, Batch Preference 包含在完整版中。创建免费账户即可在 YC Insights 中打开，紧邻每个其他 YC 批次。

查看完整申请

常见问题解答

这是 Altay Therapeutics 的真实 YC 申请吗？

不是。Y Combinator 对提交的申请保密。这是重建版：使用 Altay Therapeutics 的公开数据（发布笔记、创始人背景、产品描述）回答真实的 YC 表格问题。它展示了像 Altay Therapeutics 这样的公司会如何向 YC 自我介绍，而不是他们提交的文本。

Altay Therapeutics 是哪个 YC 批次的？

Altay Therapeutics 是 Y Combinator Winter 2020 批次的成员。

谁创立了 Altay Therapeutics？

Altay Therapeutics 由 Ali Ozes, Osman Ozes 创立。

Altay Therapeutics 做什么？

Altay develops disease-modifying therapies targeting transcription…

如何阅读完整的重建申请？

创建免费的 Round Funded 账户。YC Insights 中包含 Altay Therapeutics 的完整 26 个问题的版本，以及其他所有 YC 批次的公司信息。